{"title":"严重急性呼吸系统综合征冠状病毒2型辉瑞-BioNTech信使核糖核酸疫苗诱导的复发性巨大蜂窝组织炎样甜味综合征","authors":"P. Hirt, Lily Park, Carly E. Wallace, F. Kerdel","doi":"10.4081/dr.2023.9668","DOIUrl":null,"url":null,"abstract":"Primary and booster vaccines for COVID-19 are the most effective method of preventing infection and are generally considered safe. However, many cutaneous adverse events have been reported following vaccination. To date there have been seven reported cases of Sweet syndrome occurring following the first dose of the SARS-CoV-2 vaccine. We describe a rare case of atypical giant-cellulitis like Sweet syndrome reemerging after receiving the SARS-CoV-2 booster vaccine.","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":" ","pages":""},"PeriodicalIF":2.3000,"publicationDate":"2023-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Recurrent giant cellulitis-like sweet syndrome induced by SARS-CoV-2 Pfizer-BioNTech mRNA vaccine\",\"authors\":\"P. Hirt, Lily Park, Carly E. Wallace, F. Kerdel\",\"doi\":\"10.4081/dr.2023.9668\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Primary and booster vaccines for COVID-19 are the most effective method of preventing infection and are generally considered safe. However, many cutaneous adverse events have been reported following vaccination. To date there have been seven reported cases of Sweet syndrome occurring following the first dose of the SARS-CoV-2 vaccine. We describe a rare case of atypical giant-cellulitis like Sweet syndrome reemerging after receiving the SARS-CoV-2 booster vaccine.\",\"PeriodicalId\":11049,\"journal\":{\"name\":\"Dermatology Reports\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2023-05-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Dermatology Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4081/dr.2023.9668\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatology Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4081/dr.2023.9668","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"DERMATOLOGY","Score":null,"Total":0}
Primary and booster vaccines for COVID-19 are the most effective method of preventing infection and are generally considered safe. However, many cutaneous adverse events have been reported following vaccination. To date there have been seven reported cases of Sweet syndrome occurring following the first dose of the SARS-CoV-2 vaccine. We describe a rare case of atypical giant-cellulitis like Sweet syndrome reemerging after receiving the SARS-CoV-2 booster vaccine.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
